Mechanism
Thymosin Beta-4 (TB4, the parent molecule) is a naturally-occurring 43-amino-acid peptide present in nearly all human cells. It is the most abundant member of the beta-thymosin family.
The primary characterized mechanism is G-actin sequestration. TB4 binds monomeric G-actin in the cytoplasm, preventing premature polymerization into filamentous F-actin. This regulates the actin cytoskeleton dynamics that govern cell shape, migration, and division.
Through this and related mechanisms, TB4 has been shown in animal models to:
- Promote cell migration (relevant to wound healing)
- Reduce inflammation through nuclear-factor-κB pathway modulation
- Promote angiogenesis (new blood vessel formation)
- Support cardiac repair after ischemic injury (via epicardial progenitor cell mobilization)
“TB-500” as sold in the gray-market peptide channel is typically a synthetic peptide corresponding to a fragment of TB4 (residues 17–23, the actin-binding region) or sometimes the full 43-amino-acid sequence. The fragment-versus-full-length distinction matters mechanistically but is rarely clarified by sellers.
What the evidence shows
Animal evidence (extensive):
- Cardiac repair: TB4 administration after MI in mouse and pig models has produced consistent improvements in ejection fraction, scar reduction, and angiogenic markers. Multiple labs.
- Dermal wound healing: Accelerated re-epithelialization in rodent excisional wound models.
- Corneal injury: Improved healing after chemical burns and abrasions in rabbit models.
- Skeletal muscle: Improved repair after crush and freeze injuries.
Human evidence (limited but more substantial than BPC-157’s):
- RegeneRx Phase 2 trials in pressure ulcers and venous stasis ulcers (mid-2010s): mixed results, did not progress to Phase 3.
- Cardiac repair pilot studies in patients post-MI: small samples, short follow-up, exploratory endpoints.
- Dry eye disease (RGN-259): Phase 3 trials sponsored by RegeneRx and ReGenTree completed; mixed results that did not lead to approval.
The dry-eye program (RGN-259) is the closest TB4 has come to a regulatory submission. The trial results showed signal but not enough for approval. As of 2026, no large RCT has confirmed efficacy in any indication.
Why no breakthrough:
The TB4 development story is partly mechanistic — the molecule has many actions and identifying the right indication and dosing has been difficult — and partly commercial. Development has proceeded through a specialty-biotech sponsor (RegeneRx) without the scale of the GLP-1 programs.
Dosing literature
There is no consensus dose for human use because there is no approved indication. Clinical and gray-market protocols have used:
- Subcutaneous, intramuscular, or intravenous: 2–10 mg per dose
- Frequency: twice weekly to weekly, sometimes loading-then-maintenance protocols
- Duration: 4–8 week courses are typical in user protocols
Pharmacokinetic data in humans is sparse. Half-life estimates are short (hours), but tissue effects appear to outlast plasma exposure.
We do not endorse a dose. The numbers above describe what has been used or studied, not what is recommended.
Risks and adverse events
In published clinical work and case series, TB-500 has shown a relatively benign acute adverse-event profile at investigational doses. Reported events are mostly mild and local (injection-site reactions). No major safety signals have emerged in the human work to date.
This is not the same as “safe.”
- Long-term effects are uncharacterized. The longest published exposures are weeks; chronic-use safety profile is inferred, not measured.
- The angiogenic mechanism is a theoretical concern in patients with active malignancy. Promoting blood-vessel growth is good for ischemic tissue and bad for tumor vascularization. We have no data either way; we flag it.
- The sequestration of G-actin is a fundamental cell-biology mechanism. Effects on tissues we don’t typically measure (lymphatic, immune, vascular endothelium long-term) are not characterized.
Self-sourced TB-500 quality concerns:
The “research peptide” market contains products labeled “TB-500” that range from full-length 43-amino-acid TB4 to short fragment peptides to misidentified products. Without analytical verification, you can’t know what you’ve bought. Mass-spec studies of gray-market TB-500 samples have repeatedly found wrong sequences and contamination.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Not approved | Listed by FDA in 2023 alongside BPC-157 as substances that could not be compounded under section 503A. |
| European Union | Not approved | |
| United Kingdom | Not approved | |
| Canada | Not approved | |
| Australia | Schedule 4 | Prescription-only; not commercially available. |
| WADA | Prohibited (S2 — Peptide Hormones) | Banned in competitive sport at all times. |
The WADA prohibition is worth noting because TB-500 has been a recurring positive-test substance in equine sports and some human Olympic-sport contexts.
Where to get it
We do not currently route readers to a fulfillment partner for TB-500. Same posture as BPC-157 — unapproved regulatory status, gray-market quality variance, absence of large-trial human data.
For readers under clinical supervision for an indication where TB4 is being investigated (post-MI cardiac, refractory dry-eye, severe dermal wounds), the appropriate access path is enrollment in an active clinical trial.
(See How we make money.)
References (selected)
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005.
- Crockford D, Turjman N, Allan C, Angel J. Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010.
- Smart N et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 2011.
- Sosne G et al. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol 2015.
- ClinicalTrials.gov — RGN-259 dry eye Phase 3 results.
Quick Facts
| Also Known As | TB-500, TB4, Tβ4, Thymosin β4 |
|---|---|
| Sequence | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES |
| Molecular Formula | C212H350N56O78S |
| Molecular Weight | 4963.5 Da |
Research Parameters
| Half-Life | Unknown (plasma half-life not well characterized; cellular effects are prolonged) |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in bacteriostatic water, the solution is typically stable for up to 30 days when stored at 2-8°C. Repeated freeze-thaw cycles should be avoided. |
| Solubility | Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for injection |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C or below, protected from light and moisture |
| Storage (Reconstituted) | 2-8°C (refrigerated), protected from light, for up to 30 days |
| Typical Research Dose | 2-6 mg/kg (2000-6000 mcg/kg) in animal studies |
| Cycle Parameters | In research models, typically administered daily or every other day via subcutaneous injection for a period of 2 to 6 weeks, depending on the specific injury or repair model being studied. |
| Amino Acid Count | 2 |
Mechanism of Action
Thymosin Beta-4 exerts its effects through a combination of direct intracellular actin regulation and extracellular signaling via specific receptors and pathways. Its primary mechanism involves binding to monomeric actin (G-actin), preventing its polymerization into filaments (F-actin), thereby maintaining a pool of unpolymerized actin necessary for dynamic cytoskeletal remodeling during cell migration and repair. This cytoskeletal regulation is fundamental to its pro-migratory effects.
Extracellular Signaling via PINCH-ILK Complex: Upon release from cells, Tβ4 can bind to cell surface receptors like ATP synthase and integrin-linked kinase (ILK), activating the PINCH-ILK-parvin complex. This activation promotes cell survival, migration, and angiogenesis by upregulating anti-apoptotic factors and facilitating focal adhesion turnover.
Anti-inflammatory Pathway: Tβ4 downregulates key inflammatory mediators. It inhibits the translocation of NF-κB to the nucleus, reducing the expression of cytokines like TNF-α and IL-1β. It also promotes the expression of anti-inflammatory enzymes, contributing to a reduced inflammatory response at injury sites.
Angiogenic and Vasculogenic Activity: The peptide upregulates the expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR2. It also promotes the migration of endothelial progenitor cells (EPCs) and their differentiation, facilitating the formation of new blood vessels (angiogenesis) which is critical for supplying nutrients to healing tissues.
Stem Cell Recruitment and Differentiation: Tβ4 has been shown to recruit stem cells and progenitor cells to sites of injury. It influences the differentiation of these cells, promoting a regenerative phenotype, which is particularly notable in cardiac and neural repair models.
Research Applications
Wound Healing and Dermal Repair: Research demonstrates that Tβ4 accelerates wound closure in multiple models, including diabetic ulcers and burn injuries. It enhances keratinocyte and fibroblast migration, increases collagen deposition, and promotes re-epithelialization, leading to improved healing with reduced scarring.
Cardiovascular Repair: In models of myocardial infarction, Tβ4 administration has shown cardioprotective effects. It reduces infarct size, improves left ventricular function, and promotes the formation of new cardiomyocytes and blood vessels. The peptide appears to activate resident epicardial progenitor cells, facilitating cardiac repair.
Neuroprotection and Neural Repair: Studies indicate Tβ4 promotes neuronal survival, reduces inflammation, and enhances functional recovery after traumatic brain injury and stroke. It stimulates oligodendrogenesis and remyelination, showing potential in models of multiple sclerosis and spinal cord injury.
Ocular Surface Repair: Applied topically, Tβ4 has been shown to promote corneal wound healing in models of chemical burns and dry eye disease. It reduces inflammation, supports the regeneration of corneal epithelial cells, and improves corneal transparency.
Musculoskeletal and Tendon Repair: Research in models of tendonitis, muscle strain, and joint injury shows Tβ4 reduces inflammation, decreases fibrosis, and enhances the regeneration of muscle fibers and tendon collagen organization, leading to improved strength and functional recovery.
Safety & Side Effects
In animal studies, Thymosin Beta-4 has generally been well-tolerated with a wide therapeutic index. No significant systemic toxicity has been reported at research doses. Anecdotal reports from non-clinical use sometimes mention temporary irritation at the injection site. Theoretical concerns, based on its mechanism, include the potential for promoting undesirable angiogenesis (e.g., in pre-existing tumors) or fibrosis if dysregulated. However, these concerns are not supported by significant evidence from controlled research studies. Its role in actin sequestration is a fundamental cellular process, and endogenous levels are high, suggesting a favorable safety profile, but comprehensive long-term toxicology data is limited.
Dosage Information
This information is derived from preclinical animal research studies only and does not constitute human dosing guidelines. Typical research doses in animal models range from 2 to 6 mg/kg of body weight, administered via subcutaneous or intraperitoneal injection. In some studies, localized intramuscular injection or topical application is used. Frequency of administration in research protocols varies from daily to every other day or twice weekly. Treatment duration in these studies typically spans from one to several weeks, depending on the injury model. For in vitro studies, concentrations used are generally in the nanomolar to low micromolar range.
References
Goldstein, A.L., et al. 'Purification and biological activity of thymosin, a hormone of the thymus gland.' Proceedings of the National Academy of Sciences, 1972.
Sosne, G., et al. 'Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury.' Experimental Eye Research, 2002.
Bock-Marquette, I., et al. 'Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.' Nature, 2004.
Philp, D., et al. 'Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development.' Mechanisms of Ageing and Development, 2004.
Smart, N., et al. 'Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.' Nature, 2007.
Xiong, Y., et al. 'Neuroprotective and neurorestorative effects of thymosin beta4 treatment following experimental traumatic brain injury.' Annals of the New York Academy of Sciences, 2012.
Conte, E., et al. 'Thymosin β4 protects from liver fibrosis.' Journal of Cellular Physiology, 2018.